MAGE-A4/MAGE-A8-targeted TCR-based bispecific T cell engager in recurrent and/or refractory solid tumors: a phase 1 trial
Martin Wermke / nature - Nature Medicine, Published online: 31 May 2026; doi:10.1038/s41591-026-04455-xAs presented at the 2026 ASCO Annual Meeting, in a prespecified interim analysis of a phase 1a trial of IMA401—a new bispecific TCR-based T cell engager that binds a MAGE-A4/MAG…
AI Summary: A phase 1 trial of a TCR‑based bispecific T‑cell engager targeting MAGE‑A4 and MAGE‑A8 demonstrated early anti‑tumor activity in recurrent or refractory solid tumors, with an acceptable safety profile in dose‑finding cohorts. These results revive interest in targeting intracellular cancer antigens via T‑cell redirection, nudging immunotherapy beyond familiar checkpoint territory.
Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61
Related Stories
Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128
Teclistamab outperforms standard regimens in earlier-line relapsed myeloma / 2 days
Common asthma drug may overcome immunotherapy resistance in cancers / 11 days
Retifanlimab plus chemotherapy extends survival in advanced squamous anal cancer / 13 days
Zoldonrasib shows durable responses in KRAS G12D lung cancer / 6 wks
James P. Allison wins AACR lifetime achievement award / 7 wks
Metabolic enzyme linked to immunotherapy benefit; routing metabolites may boost response / 1 month
Atezolizumab plus FOLFOX improves DFS in Stage III dMMR colon cancer / 1 month
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Pediatric Oncology, Research Funding, Reproductive Health, Wildlife and look for the RSS link.
StackHealth Time Machine